ZA9710271B - Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies - Google Patents

Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies

Info

Publication number
ZA9710271B
ZA9710271B ZA9710271A ZA9710271A ZA9710271B ZA 9710271 B ZA9710271 B ZA 9710271B ZA 9710271 A ZA9710271 A ZA 9710271A ZA 9710271 A ZA9710271 A ZA 9710271A ZA 9710271 B ZA9710271 B ZA 9710271B
Authority
ZA
South Africa
Prior art keywords
dyslipoproteinemia
treatment
recombinant viruses
related pathologies
viruses useful
Prior art date
Application number
ZA9710271A
Inventor
Patrick Benoit
Didier Rouy
Nicolas Duverger
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA9710271B publication Critical patent/ZA9710271B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9710271A 1996-11-15 1997-11-13 Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies ZA9710271B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (en) 1996-11-15 1996-11-15 BICISTRONIC RECOMBINANT VIRUSES USEFUL FOR THE TREATMENT OF DYSLIPOPROTEINEMIA-RELATED CONDITIONS

Publications (1)

Publication Number Publication Date
ZA9710271B true ZA9710271B (en) 1998-08-21

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710271A ZA9710271B (en) 1996-11-15 1997-11-13 Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies

Country Status (14)

Country Link
EP (1) EP0941355A1 (en)
JP (1) JP2001506488A (en)
KR (1) KR20000053320A (en)
AU (1) AU721654B2 (en)
BR (1) BR9712957A (en)
CA (1) CA2271437A1 (en)
CZ (1) CZ170399A3 (en)
FR (1) FR2755975B1 (en)
HU (1) HUP9904500A3 (en)
IL (1) IL129823A0 (en)
NO (1) NO992260D0 (en)
SK (1) SK63499A3 (en)
WO (1) WO1998022606A1 (en)
ZA (1) ZA9710271B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047690A2 (en) * 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Multigene vectors
DE10039844A1 (en) * 1999-08-10 2001-04-19 Hepavec Ag Fuer Gentherapie New vector useful in the treatment of malignant disease and other hyperplasia
FR2799472B1 (en) * 1999-10-07 2004-07-16 Aventis Pharma Sa PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
JP2004511203A (en) * 2000-03-24 2004-04-15 セル　ジェネシス　インコーポレーティッド A cell-specific adenovirus vector containing an internal ribosome access site
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7179659B2 (en) 2001-04-02 2007-02-20 Agilent Technologies, Inc. Sensor surfaces for detecting analytes and methods of use
JP6004549B2 (en) * 2011-08-08 2016-10-12 アプタリス ファーマ リミテッドＡｐｔａｌｉｓ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ Method for dissolution test of composition containing digestive enzyme
WO2021031551A1 (en) * 2019-08-19 2021-02-25 南京诺惟生物科技有限公司 Replicative oncolytic adenovirus for regulating lipid metabolism and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2173082T3 (en) * 1991-08-07 2002-10-16 W French Anderson RETROVIRAL VECTORS CONTAINING INTERNAL RIBOSOME ENTRY SITES.
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.
FR2722208B1 (en) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
DE69534166T2 (en) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania RECOMBINANT ADENOVIRUS AND METHODS OF USE THEREOF
FR2731710B1 (en) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES EXPRESSING LECITHIN CHOLESTEROL ACYLTRANSFERASE AND USES IN GENE THERAPY

Also Published As

Publication number Publication date
NO992260L (en) 1999-05-10
CA2271437A1 (en) 1998-05-28
KR20000053320A (en) 2000-08-25
IL129823A0 (en) 2000-02-29
AU5125298A (en) 1998-06-10
HUP9904500A3 (en) 2002-01-28
SK63499A3 (en) 2000-05-16
NO992260D0 (en) 1999-05-10
BR9712957A (en) 2000-02-01
AU721654B2 (en) 2000-07-13
EP0941355A1 (en) 1999-09-15
CZ170399A3 (en) 1999-08-11
HUP9904500A2 (en) 2000-05-28
FR2755975A1 (en) 1998-05-22
FR2755975B1 (en) 1999-05-07
WO1998022606A1 (en) 1998-05-28
JP2001506488A (en) 2001-05-22

Similar Documents

Publication Publication Date Title
IL128736A0 (en) Methods using cre-lox for production of recombinant adeno-associated viruses
GB9616594D0 (en) System for the realization of adjustable size composed elements
ZA9710271B (en) Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies
ZA978359B (en) Novel treatment
ZA976593B (en) Novel treatment
GB2355006B (en) Materials treatment
GB9726223D0 (en) The treatment of materials
GB9608657D0 (en) Novel treatment
GB2286716B (en) The treatment of solid wastes
GB9625795D0 (en) Novel treatment
ZA974667B (en) Treatment of EAF dust.
GB9618290D0 (en) Treatment of diabetes
GB9612593D0 (en) Beta3-adrenoceptor agonists for the treatment of hypertension
GB9612752D0 (en) Novel treatment
ZA964250B (en) 2-amino-benzoxazinones for the treatment of viral infections.
GB9816355D0 (en) The treatment of viral disorders
GB9816353D0 (en) The treatment of viral disorders
IL111460A0 (en) Composition for the treatment of viral infections
GB9625652D0 (en) The treatment of aluminium surfaces
SI1068199T1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
TW303786U (en) Correction device of drawknife
GB9420956D0 (en) Virus
GB9421007D0 (en) Virus
TW298919U (en) The improved wheel-assembly of stroller
GB9422910D0 (en) Composition for the treatment of hypothyroidism